Latest News
Hansa Biopharma signs EUR115m IDEFIRIX licensing deal with SERB
19 May 2026 - Swedish biotechnology company Hansa Biopharma AB (STO:HNSA) announced on Tuesday an exclusive licensing agreement with specialty pharmaceutical company SERB S.A. for the development and commercialisation of IDEFIRIX (imlifidase) across ...
Nanjing Leads Biolabs receives Chinese approval for pivotal Phase III trial of PD-L1/4-1BB bispecific antibody
19 May 2026 - Clinical-stage biotechnology company Nanjing Leads Biolabs Co Ltd (HK:9887) announced on Monday that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE...
Accro Bioscience completes USD50m Series C financing
19 May 2026 - Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors ...
Lupin receives tentative FDA approval for Revefenacin Inhalation Solution
19 May 2026 - Global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Monday that it the US Food and Drug Administration (FDA) has granted tentative approval for its Abbreviated New Drug Application for Revefenacin Inhalatio...
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
18 May 2026 - Biosensing technology company DexCom Inc (Nasdaq: DXCM) announced on Monday that it has introduced Dexcom Flex, a new continuous glucose monitoring system designed for adults with Type 2 diabetes who are not on intensive insulin therapy...